Comparison · NCT05002569-sae
Treatment 1 vs Treatment 2: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Treatment 1 vs Treatment 2: serious adverse events. Trial comparisons, record NCT05002569-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT05002569-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.32 | 0.283 | 0.361 | wilson | |
| Risk in group 2 | 0.222 | 0.189 | 0.259 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0984 | 0.0456 | 0.151 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.44 | 1.18 | 1.76 | log | |
| Odds ratio, group 1 over group 2 | 1.65 | 1.26 | 2.17 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Treatment 1 than on Treatment 2 | 10.2 | 6.64 | 21.9 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Treatment 1 | nivolumab 480 mg and relatlimab 160 mg IV every 4 weeks (Q4W) | 174 | 543 | EG000 |
| Group 2 | Treatment 2 | nivolumab 480 mg IV Q4W | 121 | 545 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Adverse Events, Serious Adverse Events and All-Cause mortality: Approximately 27.5 Months
Source ClinicalTrials.gov
Trial
- Title
- A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma
- NCT number
- NCT05002569
- Phases
- PHASE3
- Conditions
- Melanoma
- Interventions
- Nivolumab, Nivolumab + Relatlimab Fixed Dose Combination
- Lead sponsor
- Bristol-Myers Squibb
- Results first posted
- 2026-01-08
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT05002569?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT05002569-sae